Repligen (RGEN) Reports In-Line Q2 EPS, provides guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/5/2026
- Wall Street ends higher after Democrats win Congress; data center stocks tumble
- What the Democratic sweep in the midterms means for markets
- SpaceX, Tesla slide as election risks mount, Morgan Stanley turns bullish
- CVS Health plans to split into two public companies by 2028
- AI sector outlook darkens as Democrat wins threaten $900B capex cycle
Tweet
Share
E-mailGet Alerts RGEN Hot Sheet
Price: $178.20 --0%
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
KTB, CABO, FDUS, More
Financial Fact:
Selling, general and administrative: 7.13M
Today's EPS Names:
KTB, CABO, FDUS, More
Join SI Premium – FREE
Repligen (NASDAQ: RGEN) reported Q2 EPS of $0.33, in-line with the analyst estimate of $0.33. Revenue for the quarter came in at $154 million versus the consensus estimate of $154.11 million.
GUIDANCE:
Repligen sees FY2024 EPS of $1.42-$1.49, versus the consensus of $1.45.
For earnings history and earnings-related data on Repligen (RGEN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Ecovyst Inc. (ECVT) Tops Q3 EPS by 2c
- Ardent Health Partners, Inc. (ARDT) Tops Q3 EPS by 8c; offers guidance
- UBS Upgrades Nuode New Materials Co Ltd (600110:CH) to Buy
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
